Nuvation Bio Inc 现金及现金等价物净额 : $ -58.45 (2023年12月 TTM)
Nuvation Bio Inc现金及现金等价物净额(Net Change in Cash)的相关内容及计算方法如下:
截至2023年12月, Nuvation Bio Inc 过去一季度 的 现金及现金等价物净额 为 $ 18.25。 Nuvation Bio Inc 最近12个月的 现金及现金等价物净额 为 $ -58.45。
点击上方“历史数据”快速查看Nuvation Bio Inc 现金及现金等价物净额的历史走势;
点击上方“解释说明”快速查看关于Nuvation Bio Inc 现金及现金等价物净额的详细说明;
点击上方“相关词条”快速查看与现金及现金等价物净额相关的其他指标。
Nuvation Bio Inc 现金及现金等价物净额 (NUVB.WS 现金及现金等价物净额) 历史数据
Nuvation Bio Inc 现金及现金等价物净额的历史年度,季度/半年度走势如下:
Nuvation Bio Inc 现金及现金等价物净额 年度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
现金及现金等价物净额 | 26.29 | 102.67 | -31.32 | -58.45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nuvation Bio Inc 现金及现金等价物净额 季度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
现金及现金等价物净额 | -104.90 | -212.21 | -26.22 | -3.89 | 36.37 | -37.59 | -71.03 | 19.99 | -25.67 | 18.25 |
Nuvation Bio Inc 现金及现金等价物净额 (NUVB.WS 现金及现金等价物净额) 计算方法
截至2023年12月,Nuvation Bio Inc过去一年的现金及现金等价物净额为:
现金及现金等价物净额 | = | 年度 经营活动产生的现金流量净额 | + | 年度 投资活动产生的现金流量净额 | + | 年度 筹资活动产生的现金流量净额 | + | 年度 汇率变动对现金及现金等价物的影响 |
= | -68.00 | + | 8.92 | + | 0.63 | + | 0.00 | |
= | -58.45 |
截至2023年12月,Nuvation Bio Inc 过去一季度 的现金及现金等价物净额为:
现金及现金等价物净额 | = | 季度 经营活动产生的现金流量净额 | + | 季度 投资活动产生的现金流量净额 | + | 季度 筹资活动产生的现金流量净额 | + | 季度 汇率变动对现金及现金等价物的影响 |
= | -15.03 | + | 33.16 | + | 0.12 | + | 0.00 | |
= | 18.25 |
Nuvation Bio Inc 现金及现金等价物净额 (NUVB.WS 现金及现金等价物净额) 相关词条
感谢查看价值大师中文站为您提供的Nuvation Bio Inc现金及现金等价物净额的详细介绍,请点击以下链接查看与Nuvation Bio Inc现金及现金等价物净额相关的其他词条:
Nuvation Bio Inc (NUVB.WS) 公司简介
一级行业:医疗保健
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).